| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.61M | 22.61M | 20.45M | 19.10M | 18.05M | 21.01M |
| Gross Profit | 18.92M | 18.92M | 17.04M | 14.71M | 13.98M | 13.10M |
| EBITDA | 7.80M | 7.51M | 7.61M | 7.11M | 5.38M | 5.41M |
| Net Income | 6.98M | 6.98M | 5.96M | 5.59M | 4.00M | 4.12M |
Balance Sheet | ||||||
| Total Assets | 55.33M | 55.33M | 51.60M | 50.58M | 49.32M | 55.05M |
| Cash, Cash Equivalents and Short-Term Investments | 28.57M | 28.57M | 25.15M | 23.99M | 21.46M | 24.07M |
| Total Debt | 509.97K | 509.97K | 481.02K | 747.11K | 2.97M | 6.70M |
| Total Liabilities | 5.81M | 5.81M | 4.74M | 4.70M | 6.42M | 9.91M |
| Stockholders Equity | 49.52M | 49.52M | 46.85M | 45.88M | 42.90M | 45.14M |
Cash Flow | ||||||
| Free Cash Flow | 8.40M | 8.40M | 6.89M | 7.96M | 6.05M | 5.08M |
| Operating Cash Flow | 8.42M | 8.42M | 6.96M | 8.86M | 6.10M | 5.40M |
| Investing Cash Flow | 169.00 | 169.00 | -100.71K | -903.19K | 1.32M | -318.87K |
| Financing Cash Flow | -5.01M | -5.01M | -5.70M | -5.43M | -10.03M | -1.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $286.51M | 45.33 | 14.48% | 0.49% | 10.53% | 21.98% | |
| ― | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
| ― | $280.23M | ― | -25.48% | ― | -28.45% | -224.48% | |
| ― | $239.45M | ― | -22.60% | ― | -6.88% | 15.83% | |
| ― | $226.19M | ― | -28.14% | ― | 14.78% | 21.87% | |
| ― | $268.65M | -11.97 | -18.25% | ― | -0.73% | 67.98% | |
| ― | $242.30M | 1.38 | ― | 11.68% | -17.17% | 497.89% |
Repositrak’s recent earnings call painted a picture of robust financial health, underscored by impressive revenue and profitability growth. The company demonstrated effective cash management and delivered positive returns to shareholders. However, the call also highlighted concerns about rising operating expenses and the potential impact of tariffs on future performance.
ReposiTrak reported a successful fiscal year ending June 30, 2025, with an 11% increase in full-year revenue to $22.6 million and a 17% rise in net income to $7.0 million. The company has shifted its strategy to a supplier-centric model, enhancing engagement with individual suppliers and expanding cross-selling opportunities, which has contributed to its revenue growth and improved financial metrics, such as a 24% increase in operating income. ReposiTrak ended the year with $28.6 million in cash and no debt, and announced a 10% increase in its quarterly dividend, reflecting strong financial health and a commitment to returning capital to shareholders.
The most recent analyst rating on (TRAK) stock is a Buy with a $18.50 price target. To see the full list of analyst forecasts on ReposiTrak stock, see the TRAK Stock Forecast page.
ReposiTrak, a leader in food traceability and regulatory compliance solutions, offers a comprehensive suite of cloud-based applications for retailers, suppliers, and wholesalers to enhance operational controls and ensure compliance. The company recently reported a robust financial performance for the fiscal year ending June 30, 2025, with significant increases in revenue and net income.
On September 19, 2025, ReposiTrak, Inc. announced a quarterly cash dividend of $0.02 per share, payable on November 14, 2025, to shareholders of record as of September 30, 2025. This marks the third increase in the company’s dividend since its establishment, reflecting ReposiTrak’s ongoing commitment to returning value to its shareholders.
The most recent analyst rating on (TRAK) stock is a Buy with a $18.50 price target. To see the full list of analyst forecasts on ReposiTrak stock, see the TRAK Stock Forecast page.